Israeli innovations are earning worldwide recognition at a break-neck pace this year. The latest two innovations to be approved for market use are an ingestible video camera and a drug for the treatment of Multiple Sclerosis.
A revolutionary device, developed by the Givun Imaging firm in Yokneam, Israel, was approved for use by the US Food and Drug Administration. The device is an ingestible video camera, which fits inside a pill. The tiny device, only 2.6 cm long and 1 cm in diameter, consists of a miniature video camera, a light, battery, transmitter and antenna. The camera?s receiver is placed on the patient?s belly. The pill-camera can be used to view the small intestine from the inside, in order to diagnose cancer, polyps, hemorrhaging or other disorders in the digestive track. The FDA deemed the device completely safe and effective.
Meanwhile, the European Union?s Commission of the European Communities has approved marketing of Copaxone® (glatiramer acetate), a Multiple Sclerosis treatment developed by the Israeli pharmaceutical company, Teva. The drug is the first and only non-interferon immunomodulator for the treatment of relapsing-remitting Multiple Sclerosis. Teva plans to begin marketing the product in the EU this year.
The first innovative drug to be developed in Israel and to receive FDA approval, Copaxone® has already been approved for marketing in 22 countries around the world: USA, Canada, Israel, Argentina, Slovenia, Yugoslavia, Belarus, Russia, Brazil, Ukraine, Hungary, Australia, Romania, Switzerland, Slovakia, Latvia, Turkey, Czech Republic, Poland, U.K., New Zealand, and Croatia.
A revolutionary device, developed by the Givun Imaging firm in Yokneam, Israel, was approved for use by the US Food and Drug Administration. The device is an ingestible video camera, which fits inside a pill. The tiny device, only 2.6 cm long and 1 cm in diameter, consists of a miniature video camera, a light, battery, transmitter and antenna. The camera?s receiver is placed on the patient?s belly. The pill-camera can be used to view the small intestine from the inside, in order to diagnose cancer, polyps, hemorrhaging or other disorders in the digestive track. The FDA deemed the device completely safe and effective.
Meanwhile, the European Union?s Commission of the European Communities has approved marketing of Copaxone® (glatiramer acetate), a Multiple Sclerosis treatment developed by the Israeli pharmaceutical company, Teva. The drug is the first and only non-interferon immunomodulator for the treatment of relapsing-remitting Multiple Sclerosis. Teva plans to begin marketing the product in the EU this year.
The first innovative drug to be developed in Israel and to receive FDA approval, Copaxone® has already been approved for marketing in 22 countries around the world: USA, Canada, Israel, Argentina, Slovenia, Yugoslavia, Belarus, Russia, Brazil, Ukraine, Hungary, Australia, Romania, Switzerland, Slovakia, Latvia, Turkey, Czech Republic, Poland, U.K., New Zealand, and Croatia.